Looking into PT level for each drug class, majorities of AEs with substantial disparity in reporting rate between genders were dominated by women, including urinary tract and genital infection after SGLT2i treatment, edema after TZD treatment, hyperglycemia in insulin users, and UTI in DPP-4i users. The gene discussed is INS; the disease is bacterial urinary tract infection.